Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Cash from Operations: 2020-2025

Historic Cash from Operations for iSpecimen (ISPC) over the last 5 years, with Sep 2025 value amounting to -$2.0 million.

  • iSpecimen's Cash from Operations fell 88.58% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.9 million, marking a year-over-year decrease of 58.69%. This contributed to the annual value of -$8.3 million for FY2024, which is 42.29% down from last year.
  • Per iSpecimen's latest filing, its Cash from Operations stood at -$2.0 million for Q3 2025, which was down 958.92% from -$192,234 recorded in Q2 2025.
  • In the past 5 years, iSpecimen's Cash from Operations registered a high of $345,141 during Q4 2023, and its lowest value of -$6.1 million during Q3 2021.
  • Over the past 3 years, iSpecimen's median Cash from Operations value was -$1.6 million (recorded in 2023), while the average stood at -$1.6 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 5,253.35% in 2021, then spiked by 266.45% in 2023.
  • Quarterly analysis of 5 years shows iSpecimen's Cash from Operations stood at -$1.3 million in 2021, then skyrocketed by 84.29% to -$207,354 in 2022, then spiked by 266.45% to $345,141 in 2023, then slumped by 1,135.14% to -$3.6 million in 2024, then slumped by 88.58% to -$2.0 million in 2025.
  • Its Cash from Operations was -$2.0 million in Q3 2025, compared to -$192,234 in Q2 2025 and -$1.1 million in Q1 2025.